OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Palese on Emerging Technologies in Benign Prostatic Hyperplasia

September 10th 2021

Michael A. Palese, MD, discusses emerging technologies in benign prostatic hyperplasia.

Dr. Badani on Utilizing Multiport Robotic Retroperitoneal Partial Nephrectomies in RCC

September 10th 2021

Ketan K. Badani, MD, discusses the utility of multiport robotic retroperitoneal partial nephrectomies in renal cell carcinoma (RCC).

Dr. Anderson on Updated KarMMa Data With Ide-Cel in Multiple Myeloma

September 10th 2021

Larry Anderson, MD, PhD, discusses outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma, as demonstrated in the phase 2 KarMMa trial.

Dr. Martin on the Utility of Quadruplet-Based Regimens in Relapsed/Refractory Multiple Myeloma

September 10th 2021

Thomas G. Martin, MD, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma.

Dr. Evangelist on the Goals of the MYLUNG Consortium in Lung Cancer

September 10th 2021

Makenzi Evangelist, MD, discusses the goals of the MYLUNG Consortium in lung cancer.

Dr. Haakensen on Exclusion Criteria of a Named Patient Use Program in NSCLC

September 10th 2021

Vilde D. Haakensen, MD, PhD, discusses exclusion criteria for the Oslo University Hospital Named Patient Use program for adjuvant durvalumab in non–small cell lung cancer.

Dr. Sanchorawala on the Impact of Depth of Renal and Cardiac Response on Survival in AL Amyloidosis

September 10th 2021

Vaishali Sanchorawala, MD, discusses the impact of renal and cardiac response on survival in patients with light chain amyloidosis.

Dr. Shah on the Clinical Implications of Ide-Cel in Relapsed/Refractory Myeloma

September 10th 2021

Nina Shah, MD, discusses the clinical implications of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Dr. Cohen on the Importance of Patient Selection for HIPEC Surgery in CRC

September 9th 2021

Stacey A. Cohen, MD, discusses the importance of patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

Dr. Robert on Evaluating Trends in Biomarker Testing in Metastatic NSCLC

September 9th 2021

Nicholas Robert, MD, discusses the importance of evaluating trends in biomarker testing in metastatic non–small cell lung cancer.

Dr. Blakely on Utilizing Osimertinib in Resectable EGFR-Mutant NSCLC

September 9th 2021

Collin Blakely MD, PhD, discusses the rationale for utilizing osimertinib in resectable EGFR-mutant non–small cell lung cancer.

Dr. Danilov on the Utility of BTK Inhibitors in CLL

September 8th 2021

Alexey V. Danilov, MD, PhD, discusses the utility of BTK inhibitors as a treatment option for patients with chronic lymphocytic leukemia.

Dr. Patel on the Integration of CAR T-Cell Therapy in Multiple Myeloma

September 8th 2021

Krina K. Patel, MD, MSc, discusses the integration of CAR T-cell therapy into the treatment paradigm of relapsed/refractory multiple myeloma.

Dr. Raghav on First-Line Treatment Options in CRC

September 7th 2021

Kanwal Raghav, MBBS, MD, discusses first-line treatment options for patients with colorectal cancer.

Dr. Zhen on Advancements in Gastroenteropancreatic Neuroendocrine Tumors

September 7th 2021

David Zhen, MD, discusses advancements in the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Dr. Abdul Razak on Initial Findings With Durvalumab Plus Olaparib or Cediranib in Leiomyosarcoma

September 7th 2021

Albiruni Ryan Abdul Razak, MRCP, MBBCh, discusses initial findings from a phase 2 trial evaluating the utility of durvalumab in combination with olaparib or cediranib in leiomyosarcoma.

Dr. Ready on Selecting Between Frontline Atezolizumab and Durvalumab in ES-SCLC

September 7th 2021

Neal E. Ready, MD, PhD, discusses selecting between frontline chemotherapy plus atezolizumab or durvalumab in extensive-stage small cell lung cancer.

Dr. Parikh on Future Research Directions in Hepatitis C-Related HCC

September 7th 2021

Neehar Parikh, MD, discusses future research directions in hepatitis C-related hepatocellular carcinoma.

Dr. Llovet on Considering Safety Profiles During Treatment Selection in HCC

September 7th 2021

Josep Llovet, MD, discusses the adverse events cause by treatments in hepatocellular carcinoma.

Dr. Pinato on Guidelines for Toxicity Management in HCC

September 5th 2021

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).